Decision of Anticoagulation in Nonvalvular Atrial Fibrillation in the Real World in the Non-Antivitamin K Anticoagulants Era

Decision of Anticoagulation in Nonvalvular Atrial Fibrillation in the Real World in the Non-Antivitamin K Anticoagulants Era

<i>Background.</i> Patients with nonvalvular atrial fibrillation (NVAF) have five times higher risk of stroke than the general population. Anticoagulation (ACO) in NVAF is a class I indication after assessing the CHA2DS2-VASc and HAS-BLED scores. However, in the real world, NVAF patients...

Full description

Bibliographic Details
Main Authors: Gabriela Silvia Gheorghe, Andreea Simona Hodorogea, Andrei Cristian Dan Gheorghe, Dragoș Emanuel Popa, Simona Vulpe, Cristina Georgescu, Ruxandra Bănică, Andrei Gorgian Florescu, Elena Cristiana Trușcă, Omer Eden, Ana Ciobanu, Irina Pârvu
Format: Article
Language:English
Published: MDPI AG 2022-07-01
Series:Healthcare
Subjects:
atrial fibrillation
antivitamin K anticoagulants
non-antivitamin K anticoagulants
CHA2DS2-VASc
HASBLED
CCI
Online Access:https://www.mdpi.com/2227-9032/10/7/1333

Internet

https://www.mdpi.com/2227-9032/10/7/1333

Similar Items